W
Winnie Yeo
Researcher at The Chinese University of Hong Kong
Publications - 291
Citations - 19511
Winnie Yeo is an academic researcher from The Chinese University of Hong Kong. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 60, co-authored 282 publications receiving 16440 citations. Previous affiliations of Winnie Yeo include University of Hong Kong.
Papers
More filters
Journal ArticleDOI
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry,Bruno Sangro,Thomas Yau,Todd S. Crocenzi,Masatoshi Kudo,Chiun Hsu,Tae You Kim,Su Pin Choo,Jörg Trojan,Theodore H. Welling,Tim Meyer,Yoon-Koo Kang,Winnie Yeo,Akhil Chopra,Jeffrey Anderson,Christine Dela Cruz,Lixin Lang,Jaclyn Neely,Hao Tang,Homa Dastani,Ignacio Melero +20 more
TL;DR: Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma, and safety and tolerability for the escalation phase and objective response rate were primary endpoints.
Journal ArticleDOI
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
Philip J. Johnson,Sarah Berhane,Chiaki Kagebayashi,Shinji Satomura,M Teng,Helen L. Reeves,James O'Beirne,Richard Fox,Anna Skowronska,D. Palmer,Winnie Yeo,Frankie Mo,Paul B.S. Lai,Mercedes Iñarrairaegui,Stephen L. Chan,Bruno Sangro,Rebecca A. Miksad,Toshifumi Tada,Takashi Kumada,Hidenori Toyoda +19 more
TL;DR: The ALBI grade offers a simple, evidence-based, objective, and discriminatory method of assessing liver function in HCC that has been extensively tested in an international setting and eliminates the need for subjective variables such as ascites and encephalopathy, a requirement in the conventional C-P grade.
Journal ArticleDOI
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors
Winnie Yeo,Paul K.S. Chan,Sheng Zhong,Wing M. Ho,Joyce Steinberg,John S. Tam,Pun Hui,Nancy Leung,Benny Zee,Philip J. Johnson +9 more
TL;DR: In patients with chronic HBV infection under chemotherapy, HBV reactivation occurs in nearly 20% of them and accounts for 44% of hepatitis cases; the risk factors identified include male sex, younger age, HBeAg seropositive, and the diagnosis of lymphoma.
Journal ArticleDOI
Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab
Winnie Yeo,Tung C. Chan,Nancy Leung,Wai Y. Lam,Frankie Mo,Miu Ting Chu,Henry Lik-Yuen Chan,Edwin P. Hui,Kenny I.K. Lei,Tony Mok,Paul K.S. Chan +10 more
TL;DR: Close monitoring until at least 6 months after anticancer therapy is required, with an alternative approach of prophylactic antiviral therapy to prevent this potentially fatal condition.
Journal ArticleDOI
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
Winnie Yeo,Tony Mok,Benny Zee,Thomas W.T. Leung,Paul B.S. Lai,Wan Y. Lau,Jane Koh,Frankie Mo,Simon C.H. Yu,Anthony T.C. Chan,Pun Hui,Brigette B.Y. Ma,Kwok Chi Lam,Wing M. Ho,Herman T. Wong,Amanda Tang,Philip J. Johnson +16 more
TL;DR: Although patients on PIAF had a higher overall response rate and better survival than patients on doxorubicin, the differences were not statistically significant and the prognosis of patients with unresectable HCC remains poor.